Oxford Immunotec
(OXFD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -22,174 | -8,664 | -14,883 | -13,104 |
| Depreciation Amortization | 1,742 | 1,101 | 801 | 630 |
| Accounts receivable | -2,311 | 637 | -3,103 | -1,042 |
| Accounts payable and accrued liabilities | -109 | 483 | 196 | 455 |
| Other Working Capital | -2,960 | 965 | -1,863 | -440 |
| Other Operating Activity | 5,035 | -141 | 4,482 | 844 |
| Operating Cash Flow | $-20,777 | $-5,619 | $-14,370 | $-12,657 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -3,014 | -1,787 | -1,482 | -1,238 |
| Net Acquisitions | -1,716 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -354 | -205 | -79 | -1 |
| Other Investing Activity | -297 | 20 | -394 | -360 |
| Investing Cash Flow | $-5,027 | $-1,767 | $-1,876 | $-1,598 |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | N/A | 4,842 | 5,500 | N/A |
| Debt Issued | N/A | 6,582 | 0 | N/A |
| Debt Repayment | -165 | -6,068 | -60 | -102 |
| Common Stock Issued | 14 | 63,901 | 1 | 5 |
| Other Financing Activity | 0 | 1,442 | 20,776 | 9,978 |
| Financing Cash Flow | $-151 | $70,699 | $26,217 | $9,881 |
| Exchange Rate Effect | -374 | 603 | 273 | 64 |
| Beginning Cash Position | 76,494 | 12,578 | 2,334 | 6,644 |
| End Cash Position | 50,165 | 76,494 | 12,578 | 2,334 |
| Net Cash Flow | $-26,329 | $63,916 | $10,244 | $-4,310 |
| Free Cash Flow | ||||
| Operating Cash Flow | -20,777 | -5,619 | -14,370 | -12,657 |
| Capital Expenditure | -3,014 | -1,809 | -1,482 | -1,238 |
| Free Cash Flow | -23,791 | -7,428 | -15,852 | -13,895 |